Ratings by Baird (Jack Allen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2026 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Outperform) |
64.11 (114.33) |
78.33% | Details | |
| 2/13/2026 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2026 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2026 | Instil Bio Inc | TIL | Downgrade | Neutral (Outperform) |
12.29 (8.87) |
-27.83% | Details | |
| 12/29/2025 | Mereo BipPharma Group | MREO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/23/2025 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2025 | Mereo BipPharma Group | MREO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2025 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2025 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2025 | Vor Biopharma, Inc. | VOR | Upgrade | Outperform (Neutral) |
32.29 (15.12) |
-53.17% | Details | |
| 10/2/2025 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2025 | Lineage Cell Therapeutics Inc. | LCTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2025 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 7/17/2025 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2025 | Vor Biopharma, Inc. | VOR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/15/2025 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/8/2025 | Vor Biopharma, Inc. | VOR | Downgrade | Neutral (Outperform) |
0.54 (15.12) |
2700% | Details | |
| 2/21/2025 | bluebird bio | BLUE | Downgrade | Neutral (Outperform) |
7.04 (4.97) |
-29.4% | Details | |
| 12/16/2024 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2024 | Carisma Therapeutics Inc | CARM | Downgrade | Neutral (Outperform) |
0.69 (0.15) |
-78.26% | Details | |
| 11/15/2024 | MiNK Therapeutics | INKT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2024 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2024 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2024 | Taysha Gene Therapies | TSHA | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/30/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/24/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/11/2024 | Instil Bio Inc | TIL | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/10/2024 | bluebird bio | BLUE | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/1/2024 | Lineage Cell Therapeutics Inc. | LCTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/25/2024 | Voyager Therapeutics | VYGR | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/25/2024 | bluebird bio | BLUE | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/19/2024 | Instil Bio Inc | TIL | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/19/2024 | Mereo BipPharma Group | MREO | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/17/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/16/2024 | Instil Bio Inc | TIL | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/13/2024 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | Instil Bio Inc | TIL | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/6/2024 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2024 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/24/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/13/2024 | Mereo BipPharma Group | MREO | New Coverage | Outperform (N/A) |
3.52 (0.39) |
-88.92% | Details | |
| 5/17/2024 | BioMarin Pharmaceutical Inc. | BMRN | Downgrade | Neutral (Outperform) |
80.40 (61.12) |
-23.98% | Details | |
| 5/13/2024 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | CRISPR Therapeutics | CRSP | Maintain | Neutral (N/A) |
|
Details | ||
| 2/29/2024 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 1/17/2024 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/3/2024 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2023 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2023 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2023 | Immunocore Holdings | IMCR | New Coverage | Outperform (N/A) |
42.85 (32.94) |
-23.13% | Details | |
| 9/26/2023 | Frequency Therapeutics | FREQ | Downgrade | Neutral (Outperform) |
0.38 (0.30) |
-21.05% | Details | |
| 8/15/2023 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2023 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2023 | Decibel Therapeutics Inc | DBTX | Downgrade | Neutral (Outperform) |
2.79 (4.91) |
75.99% | Details | |
| 8/4/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/28/2023 | Homology Medicines | FIXX | Downgrade | Neutral (Outperform) |
1.03 (0.93) |
-9.71% | Details | |
| 6/20/2023 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Voyager Therapeutics | VYGR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2023 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/14/2023 | Carisma Therapeutics Inc | CARM | New Coverage | Outperform (N/A) |
3.04 (0.69) |
-77.3% | Details | |
| 4/14/2023 | Arcellx Inc. | ACLX | New Coverage | Outperform (N/A) |
28.26 (64.11) |
126.86% | Details | |
| 3/24/2023 | Vor Biopharma, Inc. | VOR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2023 | MiNK Therapeutics | INKT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/7/2023 | CRISPR Therapeutics | CRSP | New Coverage | Neutral (N/A) |
50.84 (56.50) |
11.13% | Details | |
| 3/7/2023 | bluebird bio | BLUE | New Coverage | Outperform (N/A) |
5.09 (7.04) |
38.31% | Details | |
| 3/3/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/14/2023 | Frequency Therapeutics | FREQ | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2023 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/23/2023 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2023 | Fate Therapeutics | FATE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2023 | Allogene | ALLO | Upgrade | Outperform (Neutral) |
5.80 (2.30) |
-60.34% | Details | |
| 12/9/2022 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2022 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Allogene | ALLO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/2/2022 | Frequency Therapeutics | FREQ | New Coverage | Outperform (N/A) |
1.73 (0.30) |
-82.66% | Details | |
| 11/2/2022 | Lineage Cell Therapeutics Inc. | LCTX | New Coverage | Outperform (N/A) |
1.38 (1.85) |
34.06% | Details | |
| 11/1/2022 | Instil Bio Inc | TIL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2022 | Taysha Gene Therapies | TSHA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2022 | Renovacor, Inc. | RCOR | New Coverage | Outperform (N/A) |
1.89 (3.20) |
69.31% | Details | |
| 6/3/2022 | Fate Therapeutics | FATE | New Coverage | Outperform (N/A) |
22.63 (1.33) |
-94.12% | Details | |
| 6/3/2022 | Allogene | ALLO | New Coverage | Neutral (N/A) |
7.70 (2.30) |
-70.13% | Details | |
| 6/3/2022 | Voyager Therapeutics | VYGR | New Coverage | Outperform (N/A) |
6.13 (3.90) |
-36.38% | Details | |
| 6/3/2022 | Homology Medicines | FIXX | New Coverage | Outperform (N/A) |
1.45 (0.93) |
-35.86% | Details | |
| 6/3/2022 | Intellia Therapeutics | NTLA | New Coverage | Neutral (N/A) |
42.86 (13.44) |
-68.64% | Details | |
| 3/9/2022 | Taysha Gene Therapies | TSHA | New Coverage | Outperform (N/A) |
5.74 (4.57) |
-20.38% | Details | |
| 12/3/2021 | Vor Biopharma, Inc. | VOR | New Coverage | Outperform (N/A) |
11.32 (15.12) |
33.57% | Details | |
| 11/9/2021 | MiNK Therapeutics | INKT | New Coverage | Outperform (N/A) |
17.38 (10.28) |
-40.85% | Details | |
| 10/22/2021 | Decibel Therapeutics Inc | DBTX | New Coverage | Outperform (N/A) |
7.47 (4.91) |
-34.27% | Details | |
| 8/13/2021 | Instil Bio Inc | TIL | New Coverage | Outperform (N/A) |
16.27 (12.29) |
-24.46% | Details |
